Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East

IntroductionHigh-dose methotrexate (HDMTX) therapy is a cornerstone in treating pediatric and adult cancers, namely, acute lymphoblastic leukemia, non-Hodgkin lymphoma, and osteosarcoma, due to its capability to penetrate the blood–brain barrier. Despite its therapeutic benefits, HDMTX poses signifi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mubarak Al Manasour, Ahmad Absi, Ahmad Alhuraiji, Muhammad Faisal Khanani, Kayane Mheidly, Mohamed Elsaid, Walid Ballourah, Murtadha Al-Khabori, Naser Al Zain, Nisreen Khalifa, Rawad Rihani, Shaker Abdallah, Yasser Wali
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2025-11-01
Colección:Frontiers in Oncology
Materias:
acute kidney injury
acute lymphoblastic leukemia
delayed methotrexate elimination
glucarpidase
hyperhydration
leucovorin
Acceso en línea:https://www.frontiersin.org/articles/10.3389/fonc.2025.1660937/full
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares